Dramatic responses to therapy in rare tumors: Case 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1579-1580

  Chacón, Reinaldo ^a   Tossen, Gabriela ^a   Loria, Fernando Sanchez ^a   Chacón, Matías ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; EPIRUBICIN; ETOPOSIDE; THALIDOMIDE; VIMENTIN; ANGIOGENESIS INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIODIAGNOSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; ADRENAL CORTEX TUMOR; CARCINOMA;

ADRENAL CORTEX NEOPLASMS; ADULT; ANGIOGENESIS INHIBITORS; CARCINOMA; FEMALE; HUMANS; THALIDOMIDE;

EID: 14944378110     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.195     Document Type: Article

References (4)

1. Van Slooten H, Moolenaar AJ, Van Seters AP: The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic implications of serum levels monitoring. Eur J Cancer Clin Oncol 20:47-53, 1984
2. Haak HR, Hermans J, Van de Velde CS: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 69:947-951, 1994
3. Bonacci R, Gigliotti A, Baudin E: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma: Reseau Comete INSERM. Br J Cancer 78:546-549, 1998
4. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994